Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells
Files in This Item:
|Coyle & Kinsella Trog & Rosi on TP Prm3 BiochemPharm2006.pdf||2.31 MB||Adobe PDF||Download|
|Title:||Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells||Authors:||Coyle, Adrian T.
Kinsella, B. Therese
|Permanent link:||http://hdl.handle.net/10197/3149||Date:||28-Apr-2006||Online since:||2011-09-02T14:35:05Z||Abstract:||The human thromboxane (TX)A2 receptor (TP) gene encodes two TP isoforms, TPalpha and TP beta that are regulated by distinct promoters designated promoter (Prm) 1 and Prm3, respectively. Previous studies established that 15d-delta 12,14-prostaglandin J2 (15d-PGJ2) selectively inhibits Prm3 activity and TP beta expression through a peroxisome proliferator-activated receptor (PPAR)gamma mechanism without affecting Prm1 activity or TPalpha expression in human megakaryocytic erythroleukemia (HEL) 92.1.7 cells. Herein, we investigated the effect of synthetic thiazolidinedione (TZD) PPARgamma ligands rosiglitazone and troglitazone on TP gene expression in HEL cells. Like 15d-PGJ2, both TZDs suppressed Prm3 activity, TPbeta mRNA expression and TP-mediated calcium mobilization without affecting Prm1 or TPalpha mRNA expression. However, unlike 15d-PGJ2, both TZDs mediated their PPARgamma-dependent effects through trans-repression of an activator protein-1 (AP-1) element, a site previously found to be critical for basal Prm3 activity. These data provide further evidence for the role of PPARgamma in regulating the human TP gene; they highlight further differences in TPalpha and TPbeta expression/regulation and point to essential differences between natural and synthetic PPARgamma agonists in mediating those effects.||Funding Details:||Health Research Board||Type of material:||Journal Article||Publisher:||Elsevier||Journal:||Biochemical Pharmacology||Volume:||71||Issue:||9||Start page:||1308||End page:||1323||Copyright (published version):||2006 Elsevier Inc.||Keywords:||Thromboxane receptor; Promoter; Peroxisome proliferator-activated receptor (delta); Thiazolidinedione; 15-deoxy -(grdelta)12,14-prostaglandin J2||Subject LCSH:||Thromboxanes
|DOI:||10.1016/j.bcp.2006.01.011 |||Other versions:||http://dx.doi.org/10.1016/j.bcp.2006.01.011||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Conway Institute Research Collection|
Biomolecular and Biomedical Science Research Collection
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.